| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Mepolizumab |
| Brand | Nucala® |
| Indication | Mepolizumab 100mg solution in pre-filled pen and mepolizumab 100mg solution in pre-filled syringe are indicated for severe refractory eosinophilic asthma in adults and adolescents aged 12 years and over. |
| Assessment Process | |
| Rapid review commissioned | 26/08/2019 |
| Rapid review completed | 04/11/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that mepolizumab not be considered for reimbursement under the high technology drugs arrangement at the submitted price.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act.
The HSE has approved reimbursement following confidential price negotiations October 2021.
